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Background: The Tigecycline Evaluation and Surveillance Trial (TEST) is a global antimicrobial susceptibility
surveillance study which has been ongoing since 2004. This report examines the in vitro activity of tigecycline and
comparators against clinically important pathogens collected globally between 2004 and 2013.
Methods: Antimicrobial susceptibility was determined using guidelines published by the Clinical and Laboratory
Standards Institute. The Cochran Armitage Trend Test was used to identify statistically significant changes in
susceptibility between 2004 and 2013.
Results: Among the Enterobacteriaceae susceptibility was highest to the carbapenems [imipenem 97.1%
(24,655/25,381), meropenem 97.0% (90,714/93,518)], tigecycline (97.0%, 115,361/118,899) and amikacin (96.9%,
115,200/118,899). Against Acinetobacter baumannii the highest rates of susceptibility were for minocycline
(84.5%, 14,178/16,778) and imipenem (80.0%, 3,037/3,795). The MIC90 for tigecycline was 2 mg/L. 40% (6,743/16,778) of
A. baumannii isolates were multidrug-resistant. Enterococci were highly susceptible to tigecycline and linezolid (>99%);
vancomycin resistance was observed among 2% of Enterococcus faecalis (325/14,615) and 35% of Enterococcus faecium
(2,136/6,167) globally. 40% (14,647/36,448) of Staphylococcus aureus were methicillin-resistant while 15% (2,152/14,562)
of Streptococcus pneumoniae were penicillin-resistant. Against S. aureus and S. pneumoniae susceptibility to linezolid,
vancomycin, and tigecycline was ≥99.9%. Globally, 81% (331/410) of statistically significant susceptibility changes during
the study period were decreases in susceptibility.
Conclusions: Amikacin, the carbapenems, and tigecycline were active against most gram-negative pathogens while
linezolid, tigecycline, and vancomycin retained activity against most gram-positive pathogens collected in TEST during
2004–2013.
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While the initial development of antimicrobial resistance
mechanisms may be a local event, antimicrobial resist-
ance has become a problem of global concern, usually
resulting in prolonged and expensive therapy [1]. Global
travel and migration as well as international trade have
blurred the traditional geographical boundaries between
countries and continents, enabling the rapid and global* Correspondence: dhoban@dsmanitoba.ca
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unless otherwise stated.spread of resistant organisms [2]. Numerous important
resistance mechanisms have shown alarming increases in
distribution in recent years, such as extended-spectrum
β-lactamases (ESBLs) and carbapenemases [3,4]. This
situation is further complicated by the current shortage
of new antimicrobial development, increasing the prob-
ability that today’s resistant organisms may become to-
morrow’s pan-resistant pathogens [5].
The Tigecycline Evaluation and Surveillance Trial
(TEST) is a global surveillance study which has been
ongoing since 2004. It has been designed specifically to
monitor the in vitro activity of the broad-spectrum
antimicrobial tigecycline plus comparator antimicrobialThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and gram-positive organisms. In this report, we examine
the in vitro activity of tigecycline and comparators against
a collection of gram-negative and -positive organisms col-
lected from medical centres globally between 2004 and
2013. This report updates that of Garrison et al. [6], who
examined global antimicrobial susceptibility and resistance
rates between 2004 and 2007.
Materials and methods
Materials and methods for the TEST study have been
published previously e.g. [7] with minimum inhibitory
concentrations (MICs) determined according to the broth
microdilution method of the Clinical and Laboratory
Standards Institute (CLSI) [8].
After receipt by the central laboratory, International
Health Management Associates, Inc. (IHMA, Schaumberg,
IL, USA), organism identification confirmation was carried
out on all isolates using matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF) mass spectrometry
(Bruker Daltronics, Bremen, Germany).
Antimicrobial susceptibility was determined using
breakpoints approved by the CLSI [9] with the (US)
Food and Drug Administration (FDA) breakpoints used
for tigecycline [10]. FDA tigecycline breakpoints for
Enterococcus faecalis (vancomycin-susceptible) were used
for all Enterococcus isolates in this study and penicillin oral
breakpoints (susceptible ≤0.06 mg/L, resistant ≥2 mg/L)
were used for Streptococcus pneumoniae.
Multidrug resistance
For the purposes of this manuscript, multidrug-resistant
(MDR) was defined as resistance to three or more
classes of antimicrobial agents. The classes used to define
MDR among the Enterobacteriaceae were aminoglyco-
sides (amikacin), β-lactams (ampicillin, amoxicillin/clavu-
lanate, cefepime, ceftriaxone, or piperacillin-tazobactam),
carbapenems (imipenem/meropenem), fluoroquinolones
(levofloxacin), glycylcyclines (tigecycline), and tetracy-
clines (minocycline); the classes used to define MDR
A. baumannii were aminoglycosides (amikacin), β-lactams
(cefepime, ceftazidime, ceftriaxone, or piperacillin-
tazobactam), carbapenems (imipenem/meropenem),
fluoroquinolones (levofloxacin), and tetracyclines (mino-
cycline); and the classes used to define MDR P. aeruginosa
were aminoglycosides (amikacin), β-lactams (cefepime, cef-
tazidime, or piperacillin-tazobactam), carbapenems (imipe-
nem/meropenem), and fluoroquinolones (levofloxacin).
Statistical analysis
The Cochran Armitage Trend Test was used to identify
statistically significant changes in susceptibility between
2004 and 2013. A positive change designated a statisti-
cally significant decrease in susceptibility; conversely, anegative change indicated that susceptibility had in-
creased significantly. A statistical significance cut-off
value of p < 0.01 was used in this analysis. Imipenem
and meropenem data were excluded from the statis-
tical analysis. As previously reported imipenem was
replaced by meropenem in 2006 so data for the full
period of study were not available for these two antimi-
crobials. Comparative data from 2004 and 2013 are
sometimes presented here to support statistically sig-
nificant changes in susceptibility; where 2004 and/or
2013 numbers were lower than intervening study years,




The Enterobacteriaceae accounted for 118,899 isolates
globally between 2004 and 2013. Susceptibility was
highest to imipenem (97.1%), meropenem (97.0%),
tigecycline (97.0%), and amikacin (96.9%) (Table 1).
Globally, statistically significant decreases (p < 0.001–
0.0001) in susceptibility were reported against the ma-
jority of antimicrobial agents and statistically signifi-
cant (p < 0.01) changes in susceptibility were observed
in all regions (Additional file 1: Table S1).
Among MDR Enterobacteriaceae (n = 9,372; Table 1),
statistically significant changes in susceptibility were
observed in all regions excluding the Middle East; most
of these changes (20/28) represented decreases in sus-
ceptibility (Additional file 1: Table S1).
Enterobacter spp
A total of 32,987 isolates of Enterobacter spp. were
collected between 2004 and 2013 (Table 2). High
(>95%) levels of susceptibility were observed for ami-
kacin, imipenem, meropenem, and tigecycline. Among
the 578 carbapenem-resistant (Car-R) isolates, the
highest susceptibility rate was reported for tigecycline
(83.0%).
Statistically significant decreases in global susceptibil-
ity were recorded to cefepime, ceftriaxone, minocycline,
and piperacillin-tazobactam (each p < 0.0001) between
2004 and 2013 (Additional file 1: Table S1); minocycline
global susceptibility declined between 2004 (85.5%) and
2011 (57.6%) but increased to 84.5% in 2012 and 86.1%
in 2013 (data not shown). Tigecycline susceptibility in-
creased in North America (p < 0.0001; 93.7% in 2004 and
96.4% in 2013) but decreased in Latin America [p < 0.01;
98.2% in 2004 and 83.3% in 2013 (n = 24 in 2013)].
Escherichia coli
Of 37,038 E. coli isolates collected globally, most were
susceptible to tigecycline (>99.9%), imipenem (99.4%),
meropenem (99.1%), and amikacin (98.3%) (Table 2).
Table 1 Antimicrobial activity of antimicrobial agents against Enterobacteriaceae collected globally between 2004 - 2013
MIC90 (mg/L) MIC range mg/L % susceptible % resistant
Enterobacteriaceae (n = 118,899)
AMK 8 ≤0.5 – ≥ 128 96.9 1.8
AMC ≥64 ≤0.12 –≥ 64 43.5 46.2
AMP (n = 118,648) ≥64 ≤0.5 – ≥ 64 13.0 80.4
FEP 16 ≤0.5 – ≥ 64 88.7 8.8
CRO 64 ≤0.06 –≥ 128 72.3 25.7
IPM (n = 25,381) 1 ≤0.06 –≥ 32 97.1 0.9
LVX ≥16 ≤0.008 –≥ 16 79.0 18.4
MEM (n = 93,518) 0.25 ≤0.06 –≥ 32 97.0 2.3
MIN 16 ≤0.5 – ≥ 32 74.9 13.1
TZP 64 ≤0.06 –≥ 256 84.0 9.4
TGC 1 ≤0.008 –≥ 32 97.0 0.6
Enterobacteriaceae, MDR (n = 9,372)
AMK ≥128 ≤0.5 – ≥ 128 75.4 17.8
AMC ≥64 0.25 –≥ 64 11.8 67.8
AMP (n = 9,371) ≥64 ≤0.5 – ≥ 64 0.2 99.5
FEP ≥64 ≤0.5 – ≥ 64 47.3 44.2
CRO ≥128 ≤0.06 –≥ 128 20.3 78.2
IPM (n = 1,158) 4 ≤0.06 –≥ 32 85.2 12.1
LVX ≥16 ≤0.008 –≥ 16 6.1 92.1
MEM (n = 8,214) ≥32 ≤0.06 –≥ 32 75.3 21.8
MIN ≥32 ≤0.5 – ≥ 32 12.0 81.5
TZP ≥256 ≤0.06 –≥ 256 39.5 44.0
TGC 4 ≤0.008 –≥ 32 83.2 6.9
AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; BL, β-lactamase; Car-R, carbapenem-resistant; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; IPM,
imipenem; LVX, levofloxacin; LZD, linezolid; MDR, multidrug-resistant; MEM, meropenem; MIN, minocycline; PEN, penicillin; TZP, piperacillin-tazobactam; TGC,
tigecycline; VAN, vancomycin.
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(181/37,038) of isolates globally (Table 2) but reached
2.0% (13/661) in Africa (data not shown); tigecycline
susceptibility remained high (97.2%) among these
resistant isolates.
Regionally, statistically significant decreases in suscepti-
bility were most prevalent in Asia/Pacific Rim, North
America, and Latin America (Additional file 1: Table S1).
Tigecycline susceptibility decreased significantly (p < 0.01)
in North America and globally, although the actual sus-
ceptibility rates decreased from 100% to 99.6% and from
100% to 99.8%, respectively, between 2004 and 2013.
Among carbapenem-resistant E. coli, global susceptibility
decreased to cefepime (p < 0.0001; 42.9% in 2006 and 0.0%
in 2013), ceftriaxone (p < 0.01; 16.7% in 2004 and 0.0% in
2013), and tigecycline (p < 0.01; 100% in 2004 and 80.0%
in 2013), although only 181 isolates were identified be-
tween 2004 and 2013.
ESBL production was observed among 5,178 (14.0%)
E. coli isolates globally (Table 2), ranging from 5.0%(650/12,934) in North America to 24.7% (1,049/4,239) in
Latin America and 25.9% (330/1,273) in Middle East
(data not shown). Global ESBL percentages significantly
(p < 0.0001) increased from 5.8% (148/2,549) in 2004 to
15.5% (266/1,712) in 2013, reaching a maximum of
18.8% (911/4,858) in 2012. Amikacin, imipenem, merope-
nem, and tigecycline susceptibility remained high (>94%)
among ESBL-positive isolates.
Klebsiella oxytoca
Globally, K. oxytoca (n = 6,940) were highly susceptible
(>96%) to amikacin, cefepime, imipenem, meropenem,
and tigecycline (Table 2). In Asia/Pacific Rim, statisti-
cally significant decreases in amikacin, minocycline (each
p < 0.0001), and levofloxacin (p < 0.01) susceptibility were
observed; globally, piperacillin-tazobactam susceptibility
decreased significantly (p < 0.01) while tigecycline suscep-
tibility increased significantly (p < 0.01) from 98.6% in
2004 to 99.4% in 2013 (Additional file 1: Table S1). Only
301 ESBL-producing K. oxytoca isolates were identified
Table 2 Antimicrobial activity of antimicrobial agents against members of the Enterobacteriaceae collected globally
between 2004 - 2013
MIC90 (mg/L) MIC range mg/L % susceptible % resistant
Enterobacter spp. (n = 32,987)
AMK 4 ≤0.5–≥ 128 97.2 1.8
FEP 8 ≤0.5–≥ 64 91.7 5.8
CRO 64 ≤0.06–≥ 128 61.7 35.1
IPM (n = 6,963) 1 ≤0.06–≥ 32 95.7 1.1
LVX 8 ≤0.008–≥ 16 86.8 10.7
MEM (n = 26,024) 0.25 ≤0.06–≥ 32 97.2 1.9
MIN 16 ≤0.5–≥ 32 73.7 12.5
TZP 128 ≤0.06–≥ 256 76.1 12.1
TGC 2 ≤0.008–≥ 32 95.4 1.1
Enterobacter spp., Car-R (n = 578)
AMK ≥128 ≤0.5–≥ 128 68.3 23.7
FEP ≥64 ≤0.5–≥ 64 35.6 52.2
CRO ≥128 ≤0.06–≥ 128 6.7 91.9
LVX ≥16 ≤0.008–≥ 16 39.1 54.0
MIN ≥32 ≤0.5–≥ 32 39.8 38.8
TZP ≥256 ≤0.06–≥ 256 22.5 60.7
TGC 4 0.06–16 83.0 5.2
Escherichia coli (n = 37,038)
AMK 8 ≤0.5–≥ 128 98.3 0.9
AMC 32 ≤0.12–≥ 64 66.6 14.2
AMP ≥64 ≤0.5–≥ 64 35.6 63.5
FEP 16 ≤0.5–≥ 64 88.5 9.0
CRO 64 ≤0.06–≥ 128 79.1 19.9
IPM (n = 8,091) 0.5 ≤0.06–≥ 32 99.4 0.3
LVX ≥16 ≤0.008–≥ 16 66.1 31.5
MEM (n = 28,947) ≤0.06 ≤0.06–≥ 32 99.1 0.5
MIN 16 ≤0.5–≥ 32 77.0 13.0
TZP 16 ≤0.06–≥ 256 91.3 4.4
TGC 0.5 ≤0.008–≥ 32 >99.9 <0.1
Escherichia coli, ESBL-positive (n = 5,178)
AMK 16 ≤0.5–≥ 128 94.2 2.7
AMC 32 0.25–≥ 64 31.3 28.5
AMP ≥64 1–≥ 64 0.4 99.5
FEP ≥64 ≤0.5–≥ 64 32.4 54.8
CRO ≥128 ≤0.06–≥ 128 1.3 97.5
IPM (n = 643) 0.5 ≤0.06–8 98.1 0.6
LVX ≥16 ≤0.008–≥ 16 18.1 78.5
MEM (n = 4,535) 0.12 ≤0.06–≥ 32 98.5 0.8
MIN ≥32 ≤0.5–≥ 32 63.2 22.7
TZP 64 ≤0.06–≥ 256 77.0 9.9
TGC 0.5 ≤0.008–8 >99.9 <0.1
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Table 2 Antimicrobial activity of antimicrobial agents against members of the Enterobacteriaceae collected globally
between 2004 - 2013 (Continued)
Escherichia coli, Car-R (n = 181)
AMK ≥128 ≤0.5–≥ 128 50.8 38.1
AMC ≥64 2–≥ 64 11.6 76.8
AMP ≥64 1–≥ 64 8.3 90.6
FEP ≥64 ≤0.5–≥ 64 28.2 56.4
CRO ≥128 ≤0.06–≥ 128 9.9 90.1
LVX ≥16 ≤0.008–≥ 16 22.7 71.3
MIN ≥32 ≤0.5–≥ 32 43.1 35.4
TZP ≥256 1–≥ 256 29.3 55.8
TGC 2 ≤0.008–16 97.2 1.7
Klebsiella oxytoca (n = 6,940)
AMK 4 ≤0.5–≥ 128 98.8 0.8
AMC 32 0.25–≥ 64 79.4 12.4
FEP 2 ≤0.5–≥ 64 96.1 2.4
CRO 16 ≤0.06–≥ 128 81.5 16.2
IPM (n = 1,454) 0.5 ≤0.06–≥ 32 99.2 0.5
LVX 2 ≤0.008–≥ 16 92.1 5.7
MEM (n = 5,486) 0.12 ≤0.06–≥ 32 98.8 0.8
MIN 8 ≤0.5–≥ 32 88.2 5.6
TZP ≥256 ≤0.06–≥ 256 85.1 12.5
TGC 1 ≤0.008–16 98.7 0.2
Klebsiella pneumoniae (n = 28,928)
AMK 16 ≤0.5–≥ 128 94.4 3.1
AMC 32 ≤0.12–≥ 64 67.9 20.2
FEP ≥64 ≤0.5–≥ 64 81.0 15.8
CRO ≥128 ≤0.06–≥ 128 70.1 28.8
IPM (n = 6,008) 0.5 ≤0.06–≥ 32 97.7 1.6
LVX ≥16 ≤0.008–≥ 16 77.4 19.5
MEM (n = 22,920) 0.25 ≤0.06–≥ 32 93.5 5.4
MIN 16 ≤0.5–≥ 32 71.4 18.0
TZP ≥256 ≤0.06–≥ 256 79.4 14.9
TGC 2 ≤0.008–≥ 32 95.3 0.8
Klebsiella pneumoniae, ESBL-positive (n = 5,899)
AMK 32 ≤0.5–≥ 128 83.6 9.5
AMC ≥64 ≤0.12–≥ 64 18.3 48.3
FEP ≥64 ≤0.5–≥ 64 31.9 56.6
CRO ≥128 ≤0.06–≥ 128 1.4 97.0
IPM (n = 946) 1 ≤0.06–≥ 32 91.3 6.1
LVX ≥16 ≤0.008–≥ 16 35.2 57.1
MEM (n = 4,953) 2 ≤0.06–≥ 32 88.3 9.0
MIN ≥32 ≤0.5–≥ 32 48.4 34.5
TZP ≥256 ≤0.06–≥ 256 44.3 39.2
TGC 2 ≤0.008–≥ 32 92.3 1.6
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Table 2 Antimicrobial activity of antimicrobial agents against members of the Enterobacteriaceae collected globally
between 2004 - 2013 (Continued)
Klebsiella pneumoniae, Car-R (n = 1,330)
AMK ≥128 ≤0.5–≥ 128 57.5 18.4
AMC ≥64 1–≥ 64 1.7 96.5
FEP ≥64 ≤0.5–≥ 64 7.4 85.0
CRO ≥128 ≤0.06–≥ 128 1.8 97.5
LVX ≥16 ≤0.008–≥ 16 10.1 85.9
MIN ≥32 ≤0.5–≥ 32 52.2 25.3
TZP ≥256 0.12–≥ 256 4.7 91.3
TGC 2 0.03–16 92.0 2.1
Klebsiella pneumoniae, ESBL-positive, Car-R (n = 505)
AMK ≥128 ≤0.5–≥ 128 59.8 15.6
AMC ≥64 8–≥ 64 0.8 96.2
FEP ≥64 1–≥ 64 4.8 83.6
CRO ≥128 2–≥ 128 0.0 99.6
LVX ≥16 0.015–≥ 16 6.7 88.5
MIN ≥32 ≤0.5–≥ 32 49.7 28.5
TZP ≥256 1–≥ 256 2.0 92.9
TGC 2 0.12–16 91.1 3.6
Serratia marcescens (n = 13,006)
AMK 8 ≤0.5–≥ 128 96.5 2.1
AMC ≥64 ≤0.12–≥ 64 3.3 93.9
AMP (n = 12,963) ≥64 ≤0.5–≥ 64 2.7 88.0
FEP 2 ≤0.5–≥ 64 95.2 3.5
CRO 16 ≤0.06–≥ 128 79.6 16.9
IPM (n = 2,865) 1 ≤0.06–8 92.2 1.2
LVX 2 ≤0.008–≥ 16 92.9 4.4
MEM (n = 10,141) 0.25 ≤0.06–≥ 32 97.4 1.9
MIN 8 ≤0.5–≥ 32 72.3 8.5
TZP 16 ≤0.06–≥ 256 92.4 3.2
TGC 2 ≤0.008–≥ 32 95.8 0.7
Serratia marcescens, Car-R (n = 229)
AMK ≥128 ≤0.5–≥ 128 67.7 24.9
AMC ≥64 ≤0.12–≥ 64 0.4 99.1
AMP ≥64 16–≥ 64 0.0 95.2
FEP ≥64 ≤0.5–≥ 64 51.1 39.3
CRO ≥128 ≤0.06–≥ 128 26.2 70.3
LVX ≥16 0.03–≥ 16 60.7 31.0
MIN 16 ≤0.5–≥ 32 54.6 26.6
TZP ≥256 0.25–≥ 256 45.4 41.0
TGC 4 0.12–16 83.8 4.8
AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; BL, β-lactamase; Car-R, carbapenem-resistant; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone;
ESBL, extended-spectrum β-lactamase; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MIN, minocycline; PEN, penicillin; TZP,
piperacillin-tazobactam; TGC, tigecycline; VAN, vancomycin.
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Africa to 136 in Europe.
Klebsiella pneumoniae
A total of 28,928 isolates of K. pneumoniae were col-
lected globally between 2004 and 2013. Susceptibility
was highest to imipenem (97.7%), tigecycline (95.3%),
amikacin (94.4%), and meropenem (93.5%) (Table 2).
After gradual declines in susceptibility between 2004
and 2011, susceptibility to several antimicrobials increased
between 2011 and 2013 (cefepime, susceptibility increased
by 5.8%; levofloxacin, by 8.7%; ceftriaxone, by 8.9%;
amoxicillin-clavulanate, by 9.7%; piperacillin-tazobactam,
by 14.3%; and minocycline, by 22.9%). Carbapenem resist-
ance was observed in 1330 (4.6%) isolates, with the agent
with the highest susceptibility against this subset of re-
sistant isolates being tigecycline (92.0% susceptible); 505
ESBL-positive isolates were also carbapenem-resistant
(Table 2).
Statistically significant reductions in susceptibility
among K. pneumoniae were noted to most antimicro-
bials globally as well as in Asia/Pacific Rim and Europe
(Additional file 1: Table S1). Carbapenem-resistant K.
pneumoniae demonstrated low (≤10.1%) and signifi-
cantly decreased susceptibility to amoxicillin-clavulanate,
cefepime, ceftriaxone, levofloxacin, and piperacillin-
tazobactam globally (Additional file 1: Table S1).
ESBL production, observed in 5,899 (20.4%) K. pneumo-
niae isolates globally, was highest in Africa (42.8%, 249/
582) and lowest in North America (9.5%, 983/10,366).
Susceptibility among these isolates was highest to tigecyc-
line (92.3%) and imipenem (91.3%) (Table 2). Global ESBL
percentages increased significantly (p < 0.0001) from
13.9% (289/2086) in 2004 to 18.5% (227/1229) in 2013,
achieving a maximum of 25.6% (757/2,954) in 2011.
Statistically significant decreases in antimicrobial
susceptibility were reported globally among ESBL-
positive K. pneumoniae for cefepime and minocycline
(both p < 0.0001) as well as ceftriaxone (p < 0.001), while
increases in susceptibility were recorded to amikacin (p <
0.0001) and piperacillin-tazobactam (p < 0.01) (Additional
file 1: Table S1).
Serratia marcescens
Globally, a total of 13,006 S. marcescens isolates were
collected. Susceptibility was high (>92%) to most agents
on the panel with the exceptions of ampicillin (2.7%),
amoxicillin-clavulanate (3.3%), minocycline (72.3%), and
ceftriaxone (79.6%). Carbapenem resistance was ob-
served in 229 (1.8%) isolates (Table 2).
Minocycline susceptibility decreased significantly glo-
bally (p < 0.0001; 88.8% in 2004 and 85.1% in 2013) and
in all regions bar Middle East (p < 0.0001; Additional
file 1: Table S1); minocycline susceptibility reached aglobal minimum of 48.1% in 2009. Tigecycline susceptibil-
ity decreased significantly in Asia/Pacific Rim (p < 0.001;
96.8% in 2004 and 92.5% in 2011) and Latin America (p <
0.01; 100% in 2004 and 87.0% in 2012) (Additional file 1:
Table S1).
Acinetobacter baumannii
The highest levels of in vitro susceptibility against A.
baumannii isolates (n = 16,778) in this study were re-
ported for minocycline (84.5%) and imipenem (80.0%)
(Table 3). No breakpoints are available for tigecycline,
for which a MIC90 of 2 mg/L was observed. More than
40% (6,743/16,778) of A. baumannii isolates were MDR
globally (Table 3), with rates highest in Africa (59.4%,
202/340), Middle East (67.2%, 452/673), and Latin
America (67.8%, 1,388/2,048) (data not shown); the
highest levels of susceptibility against these MDR iso-
lates was observed for minocycline (70.3% susceptible),
while tigecycline retained a MIC90 of 2 mg/L (Table 3).
Significant decreases in susceptibility were observed to
all antimicrobials with available breakpoints globally (all
p < 0.0001) (Additional file 1: Table S1). Among MDR A.
baumannii, significant reductions in global susceptibility
were noted to minocycline, and piperacillin-tazobactam
(p < 0.0001). Significant increases in MDR A. baumannii
susceptibility were observed to amikacin (p < 0.001) in
Latin America, although susceptibility was only 8.8%
during the complete study interval, and to minocycline
(p < 0.001) in Africa.
Haemophilus influenzae
A total of 15,925 isolates of H. influenzae were collected
globally. All isolates were highly susceptible (>98.5%) to
the antimicrobial agents on the panel with the exception
of ampicillin (78.3% susceptibility) (Table 3).
Globally, increased ampicillin susceptibility was re-
corded (p < 0.001; 76.3% in 2004 and 80.2% in 2012)
while decreased susceptibility was observed to ceftriaxone
(p < 0.0001; 100% in 2004 and 99.7% in 2013) and tigecyc-
line (p < 0.0001; 100% in 2004 and 95.4% in 2011 [100% in
2013]) (Additional file 1: Table S1). Significant decreases
in tigecycline susceptibility were recorded in Asia/Pacific
Rim (p < 0.001; 100% in 2004 and 92.7% in 2012) and
Latin America (p < 0.01; 100% in 2004 and 93.6% in 2012).
β-lactamase production was reported in 20.1% (3,207/
15,925) of H. influenzae isolates globally; these isolates
retained high susceptibility to most agents with the
exception of ampicillin (0.2% susceptible; Table 3). No
statistically significant changes in susceptibility were
seen among β-lactamase-positive H. influenzae.
Pseudomonas aeruginosa
Globally, 28,413 P. aeruginosa isolates were collected
between 2004 and 2013. These isolates showed a high
Table 3 Antimicrobial activity of antimicrobial agents against Acinetobacter baumannii, Haemophilus influenzae and
Pseudomonas aeruginosa collected globally between 2004 - 2013
MIC90 (mg/L) MIC range mg/L % susceptible % resistant
Acinetobacter baumannii (n = 16,778)
AMK ≥128 ≤0.5 –≥ 128 61.1 32.4
AMC ≥64 ≤0.12 –≥ 64 - -
AMP ≥64 ≤0.5 –≥ 64 - -
FEP ≥64 ≤0.5 –≥ 64 44.3 42.9
CAZ ≥64 ≤8 –≥ 64 41.2 52.1
CRO ≥128 ≤0.06 –≥ 128 23.3 54.6
IPM (n = 3,795) ≥32 ≤0.06 –≥ 32 80.0 16.8
LVX ≥16 ≤0.008 – ≥ 16 43.0 46.6
MEM (n = 12,983) ≥32 ≤0.06 –≥ 32 54.8 41.1
MIN 8 ≤0.5 –≥ 32 84.5 5.1
TZP ≥256 ≤0.06 –≥ 256 42.9 47.5
TGC 2 ≤0.008 – ≥ 32 - -
Acinetobacter baumannii, MDR (n = 6,743)
AMK ≥128 ≤0.5 –≥ 128 18.4 74.1
AMC ≥64 1 – ≥ 64 - -
AMP ≥64 ≤0.5 –≥ 64 - -
FEP ≥64 ≤0.5 –≥ 64 5.5 80.1
CAZ ≥64 ≤8 –≥ 64 4.0 90.8
CRO ≥128 ≤0.06 –≥ 128 0.7 94.6
IPM (n = 896) ≥32 0.25 –≥ 32 30.9 64.6
LVX ≥16 0.03 –≥ 16 2.4 89.3
MEM (n = 5,847) ≥32 ≤0.06 –≥ 32 11.9 84.0
MIN 16 ≤0.5 –≥ 32 70.3 11.3
TZP ≥256 ≤0.06 –≥ 256 3.0 90.5
TGC 2 ≤0.008 – ≥ 32 - -
Haemophilus influenzae (n = 15,925)
AMK 8 ≤0.5 –≥ 128 - -
AMC 1 ≤0.12 –≥ 64 99.7 0.3
AMP 32 ≤0.5 –≥ 64 78.3 19.3
FEP ≤0.5 ≤0.5 –≥ 64 99.5 -
CRO ≤0.06 ≤0.06 – 32 99.9 -
IPM (n = 3,672) 1 ≤0.06 –≥ 32 99.9 -
LVX 0.03 ≤0.008 – ≥ 16 99.9 -
MEM (n = 12,253) 0.12 ≤0.06 – 2 99.9 -
MIN 1 ≤0.5 –≥ 32 98.6 0.5
TZP ≤0.06 ≤0.06 – 64 99.8 0.2
TGC 0.25 ≤0.008 – 4 98.9 -
Haemophilus influenzae, BL-pos (n = 3,207)
AMK 8 ≤0.5 –≥ 128 - -
AMC 2 ≤0.12 –≥ 64 98.9 1.1
AMP ≥64 ≤0.5 –≥ 64 0.2 95.2
FEP ≤0.5 ≤0.5 –≥ 64 99.1 -
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Table 3 Antimicrobial activity of antimicrobial agents against Acinetobacter baumannii, Haemophilus influenzae and
Pseudomonas aeruginosa collected globally between 2004 - 2013 (Continued)
CRO ≤0.06 ≤0.06 – 16 99.9 -
IPM (n = 803) 1 ≤0.06 – 4 100 -
LVX 0.03 ≤0.008 – ≥ 16 99.8 -
MEM (n = 2,404) 0.12 ≤0.06 – 2 99.8 -
MIN 1 ≤0.5 –≥ 32 98.4 0.5
TZP ≤0.06 ≤0.06 – 64 99.7 0.3
TGC 0.25 ≤0.008 – 1 99.0 -
Pseudomonas aeruginosa (n = 28,413)
AMK 16 ≤0.5 –≥ 128 90.2 6.5
AMC ≥64 ≤0.12 –≥ 64 - -
AMP ≥64 ≤0.5 –≥ 64 - -
FEP 32 ≤0.5 –≥ 64 74.3 13.5
CAZ 32 ≤8 –≥ 64 74.0 18.1
CRO ≥128 ≤0.06 –≥ 128 - -
IPM (n = 6,303) 8 ≤0.06 –≥ 32 76.4 17.5
LVX ≥16 ≤0.008 – ≥ 16 63.9 29.5
MEM (n = 22,110) 16 ≤0.06 –≥ 32 70.3 22.3
MIN ≥32 ≤0.5 –≥ 32 - -
TZP 128 ≤0.06 –≥ 256 73.1 15.3
TGC 16 ≤0.008 – ≥ 32 - -
Pseudomonas aeruginosa, MDR (n = 3,496)
AMK ≥128 ≤0.5 –≥ 128 46.3 43.5
AMC ≥64 1 – ≥ 64 - -
AMP ≥64 ≤0.5 –≥ 64 - -
FEP ≥64 ≤0.5 –≥ 64 8.2 69.0
CAZ ≥64 ≤8 –≥ 64 11.7 77.7
CRO ≥128 2 – ≥ 128 - -
IPM (n = 557) ≥32 0.5 –≥ 32 5.9 92.1
LVX ≥16 0.03 –≥ 16 2.1 96.3
MEM (n = 2,939) ≥32 ≤0.06 –≥ 32 4.9 91.8
MIN ≥32 ≤0.5 –≥ 32 - -
TZP ≥256 0.25 –≥ 256 10.9 67.7
TGC ≥32 ≤0.008 – ≥ 32 - -
AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; BL, β-lactamase; Car-R, carbapenem-resistant; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; IPM,
imipenem; LVX, levofloxacin; LZD, linezolid; MDR, multidrug-resistant; MEM, meropenem; MIN, minocycline; PEN, penicillin; TZP, piperacillin-tazobactam; TGC,
tigecycline; VAN, vancomycin.
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sistance was reported among 12.3% (3,496/28,413) of P.
aeruginosa isolates.
Globally, statistically significant decreases in amikacin
(p < 0.01; 94.9% in 2004 and 88.5% in 2011 [95.2% in
2013]), ceftazidime (p < 0.01; 79.4% in 2004 and 68.9% in
2011 [82.4% in 2013]), and piperacillin-tazobactam (p <
0.0001; 78.5% in 2004 and 67.4% in 2011 [81.1% in
2013]) susceptibility were observed among P. aeruginosa
(Additional file 1: Table S1). Susceptibility to severalantimicrobial agents increased between 2011 and 2013:
amikacin (by 6.7%), cefepime (7.6%), ceftazidime (13.5%),
and piperacillin-tazobactam (13.7%).
Enterococcus faecalis
Global susceptibility among E. faecalis isolates (n = 14,615)
was highest to linezolid (99.8%), tigecycline (99.7%), ampi-
cillin (99.4%), and penicillin (99.2%) (Table 4).
Statistically significant reductions in ampicillin, mino-
cycline, and penicillin susceptibility (each p < 0.0001)
Table 4 Antimicrobial activity of antimicrobial agents against Enterococcus and Staphylococcus spp. collected globally
between 2004 - 2013
MIC90 (mg/L) MIC range (mg/L) % susceptible % resistant
Enterococcus faecalis (n = 14,615)
AMC 1 ≤0.03 –≥ 16 - -
AMP 2 ≤0.06 –≥ 32 99.4 0.6
CRO ≥128 ≤0.03 –≥ 128 - -
IPM (n = 3,208) 4 ≤0.12 –≥ 32 - -
LVX ≥64 ≤0.06 –≥ 64 64.9 33.9
LIN 2 ≤0.5 –≥ 16 99.8 <0.1
MEM (n = 11,407) 8 ≤0.12 –≥ 32 - -
MIN ≥16 ≤0.25 –≥ 16 34.8 28.2
PEN 4 ≤0.06 –≥ 16 99.2 0.8
TZP 8 ≤0.25 –≥ 32 - -
TGC 0.25 ≤0.008 – 2 99.7 -
VAN 2 ≤0.12 –≥ 64 97.5 2.2
Enterococcus faecalis, VR (n = 325)
AMC 2 0.06 –≥ 16 - -
AMP 4 0.12 –≥ 32 94.5 5.5
CRO ≥128 ≤0.03 –≥ 128 - -
IPM (n = 98) 8 ≤0.12 –≥ 32 - -
LVX ≥64 0.5 –≥ 64 4.9 93.5
LIN 2 ≤0.5 –≥ 16 98.5 1.2
MEM (n = 227) ≥32 ≤0.12 –≥ 32 - -
MIN ≥16 ≤0.25 –≥ 16 44.3 17.8
PEN 8 0.25 –≥ 16 94.5 5.5
TZP 16 0.5 –≥ 32 - -
TGC 0.25 ≤0.008 – 1 97.8 -
Enterococcus faecium (n = 6,167)
AMC ≥16 ≤0.03 –≥ 16 - -
AMP ≥32 ≤0.06 –≥ 32 15.6 84.4
CRO ≥128 ≤0.03 –≥ 128 - -
IPM (n = 1,162) ≥32 ≤0.12 –≥ 32 - -
LVX ≥64 ≤0.06 –≥ 64 13.1 83.6
LIN 2 ≤0.5 –≥ 16 99.2 0.3
MEM (n = 5,005) ≥32 ≤0.12 –≥ 32 - -
MIN ≥16 ≤0.25 –≥ 16 68.5 14.3
PEN ≥16 ≤0.06 –≥ 16 15.6 84.4
TZP ≥32 ≤0.25 –≥ 32 - -
TGC 0.25 ≤0.008 – 4 99.7 -
VAN ≥64 ≤0.12 –≥ 64 64.0 34.6
Enterococcus faecium, VR (n = 2,136)
AMC ≥16 ≤0.03 –≥ 16 - -
AMP ≥32 ≤0.06 –≥ 32 1.5 98.5
CRO ≥128 ≤0.03 –≥ 128 - -
IPM (n = 556) ≥32 0.5 –≥ 32 - -
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Table 4 Antimicrobial activity of antimicrobial agents against Enterococcus and Staphylococcus spp. collected globally
between 2004 - 2013 (Continued)
LVX ≥64 0.5 –≥ 64 0.8 98.8
LIN 2 ≤0.5 –≥ 16 98.4 0.7
MEM (n = 1,580) ≥32 ≤0.12 –≥ 32 - -
MIN ≥16 ≤0.25 –≥ 16 65.0 13.3
PEN ≥16 ≤0.06 –≥ 16 1.7 98.3
TZP ≥32 ≤0.25 –≥ 32 - -
TGC 0.12 ≤0.008 – 4 99.2 -
Staphylococcus aureus (n = 36,448)
AMC ≥16 ≤0.03 –≥ 16 - -
AMP ≥32 ≤0.06 –≥ 32 - -
CRO ≥128 ≤0.03 –≥ 128 - -
IPM (n = 7,302) 16 ≤0.12 –≥ 32 - -
LVX 32 ≤0.06 –≥ 64 64.1 34.3
LIN 4 ≤0.5 –≥ 16 >99.9 <0.1
MEM (n = 29,146) 16 ≤0.12 –≥ 32 - -
MIN 0.5 ≤0.25 –≥ 16 97.3 0.9
PEN ≥16 ≤0.06 –≥ 16 10.9 89.1
TZP ≥32 ≤0.25 –≥ 32 - -
TGC 0.25 ≤0.008 – 1 99.9 -
VAN 1 ≤0.12 – 4 100 0
Staphylococcus aureus, MRSA (n = 14,647)
AMC ≥16 ≤0.03 –≥ 16 - -
CRO ≥128 ≤0.03 –≥ 128 - -
IPM (n = 3,235) ≥32 ≤0.12 –≥ 32 - -
LVX ≥64 ≤0.06 –≥ 64 22.1 75.9
LIN 2 ≤0.5 –≥ 16 99.9 <0.1
MEM (n = 11,412) ≥32 ≤0.12 –≥ 32 - -
MIN 2 ≤0.25 –≥ 16 94.7 1.7
TZP ≥32 ≤0.25 –≥ 32 - -
TGC 0.25 ≤0.008 – 1 99.9 -
VAN 1 ≤0.12 – 4 99.9 0
AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; AZM, azithromycin; FEP, cefepime; CAZ, ceftazidime; CLR, clarithromycin; CLI, clindamycin; CRO,
ceftriaxone; ERY, erythromycin; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MIN, minocycline; MRSA, methicillin-resistant S. aureus; TZP,
piperacillin-tazobactam; TGC, tigecycline; VAN, vancomycin; VR, vancomycin-resistant.
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ceptibility to levofloxacin (p < 0.0001) and vancomycin
(p < 0.01) increased globally (Additional file 2: Table S2).
Minocycline susceptibility among E. faecalis decreased
from 41.8% in 2004 to 26.6% in 2010 but subsequently
increased to 36.7% in 2013.
Vancomycin resistance was observed among 325
isolates (2.2%) of E. faecalis globally; these resistant iso-
lates were highly susceptible to linezolid, tigecycline,
ampicillin, and penicillin (≥94.5%) (Table 4). Among
vancomycin-resistant (VR) isolates, ampicillin, minocy-
cline, and penicillin susceptibility decreased significantlylobally (p < 0.0001, p < 0.0001 and p < 0.001, respectively)
and in North America (each p < 0.0001) (Additional file 2:
Table S2).
Enterococcus faecium
In total, 6,167 isolates of E. faecium were submitted glo-
bally. Susceptibility was highest to tigecycline (99.7%) and
linezolid (99.2%). Among all E. faecium, 2,136 (34.6%) iso-
lates were vancomycin-resistant (Table 4).
Tigecycline susceptibility in North America decreased
significantly (p < 0.01), from 100% in 2004 to 97.9% in
2011 before returning to 100% in 2013; decreased
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ceptibility were observed in Europe, while decreases in
minocycline (p < 0.0001) and penicillin (p < 0.01) suscepti-
bility occurred in Asia/Pacific Rim (Additional file 2:
Table S2).
Globally, VR E. faecium isolates (n = 2,136) were highly
susceptible to tigecycline and linezolid (99.2% and 98.4%
susceptible, respectively) (Table 4). Global vancomycin
resistance decreased from 47.4% in 2004 (188/397) to
37.2% in 2013 (121/325), reaching a minimum of 25.8%
in 2010 (217/840). Regionally, vancomycin resistance
ranged from 12.5% (356/2,844) in Europe to 66.8%
(1,438/2,152) in North America.
A global decrease in minocycline susceptibility (p <
0.0001) was observed among VR E. faecium isolates.
Tigecycline susceptibility among VR E. faecium de-
creased significantly (p < 0.01) in North America, al-
though susceptibility through the 2004–2013 period
was high (99.2%; Additional file 2: Table S2).
Staphylococcus aureus
A total of 36,448 isolates of S. aureus were contributed
globally and susceptibility was highest to linezolid,
vancomycin, and tigecycline (≥99.9%), while 97.3% of
isolates were susceptible to minocycline (Table 4).
Levofloxacin susceptibility among S. aureus decreased
in Asia/Pacific Rim (p < 0.0001; 68.3% in 2004 and 27.9%
in 2012) and Europe (p < 0.0001; 71.5% in 2004 and
66.4% in 2012) but increased in North America (p <
0.0001; 53.0% in 2004 and 62.4% in 2013) and globally
(p < 0.0001; 59.5% in 2004 and 65.2% in 2013). Minocy-
cline susceptibility increased in Middle East (p < 0.0001;
76.5% in 2005 and 98.6% in 2013) but decreased in Asia/
Pacific Rim (p < 0.0001; 88.8% in 2004 and 62.1% in
2010 [97.1% in 2012]), Latin America (p < 0.0001; 98.5%
in 2004 and 94.1% in 2011 [98.1% in 2012]), and globally
(p < 0.01; 98.6% in 2004 and 94.8% in 2010 [99.2% in
2013]) (Additional file 2: Table S2).
More than 40% (n = 14,647) of S. aureus isolates in this
study were methicillin-resistant. MRSA global rates de-
creased slightly, from 45.0% in 2004 (1,162/2,585) to
39.6% in 2013 (666/1,682); yearly global MRSA levels de-
clined to as low as 30.5% in 2010 (1,319/4,327) (data not
shown). MRSA levels exceeded 45% in Asia-Pacific (948/
2,061), Latin America (1,904/3,901), and North America
(6,733/13,077). Linezolid, vancomycin, tigecycline, and
minocycline retained their activity against MRSA isolates
(Table 4).
Although overall susceptibility levels were low (<30%),
significant increases in levofloxacin susceptibility among
MRSA were observed in Europe (p < 0.0001; 11.8% in
2004 and 20.9% in 2012 [10.6% in 2013]), Middle East
(p < 0.0001; 17.4% in 2004 and 73.1% in 2013), North
America (p < 0.0001; 19.8% in 2004 and 32.7% in 2013),and Latin America (p < 0.01; 3.3% in 2004 and 27.8% in
2012). MRSA susceptibility to minocycline increased
significantly in Middle East (p < 0.0001; 30.4% in 2004
and 100% in 2013) but decreased in Asia/Pacific Rim
(p < 0.0001; 67.3% in 2004 and 32.4% in 2010 [96.0% in
2012]) and globally (p < 0.01; 97.6% in 2004 and 86.9%
in 2010 [98.9% in 2013]) (Additional file 2: Table S2).
Streptococcus agalactiae
Globally, 12,819 S. agalactiae isolates were collected be-
tween 2004 and 2013. Susceptibility was high to most
antimicrobial agents with the exception of minocycline, to
which only 20.6% of isolates were susceptible (Table 5).
MIC90s were low for those antimicrobial agents with
no S. agalactiae breakpoints (amoxicillin-clavulanate,
0.12 mg/L; imipenem, 0.12 mg/L; and piperacillin-
tazobactam, 0.5 mg/L).
Statistically significant decreases in susceptibility to
levofloxacin (p < 0.001; 100% in 2004 and 74.1% in 2011)
and minocycline (p < 0.01; 49.0% in 2005 and 32.0% in
2012) were observed in Asia/Pacific Rim and Latin
America, respectively; no statistically significant changes
in susceptibility were recorded globally (Additional file 2:
Table S2).
Streptococcus pneumoniae
Susceptibility among S. pneumoniae (n = 14,562) was
highest to vancomycin (100%), tigecycline, linezolid
(both 99.9%), and levofloxacin (98.9%); susceptibility to
ceftriaxone and amoxicillin-clavulanate were also high
(95.0% and 92.8%, respectively) (Table 5). Global penicillin
susceptibility among S. pneumoniae increased significantly
during this study (p < 0.0001; 58.0% in 2004 to 64.7%
in 2013) but susceptibility decreased to amoxicillin-
clavulanate, ceftriaxone, minocycline (each p < 0.0001),
and clindamycin (p < 0.001) (Additional file 2: Table S2).
Penicillin-resistant S. pneumoniae (PRSP) comprised
14.8% of the S. pneumoniae isolates in this study; rates
ranged from 11.1% (8/72) in 2013 to 18.0% (350/1,941)
in 2008 and percentages were highest in Middle East
(24.7%, 114/461), Africa (28.1%, 63/224), and Asia/Pacific
Rim (30.1%, 296/985) (data not shown). Vancomycin, tige-
cycline, linezolid, and levofloxacin retained activity against
these resistant isolates; however, susceptibility to the β-
lactam and macrolide antimicrobials and minocycline de-
creased dramatically against PRSP, as much as 75.3% for
meropenem (Table 5).
Statistically significant decreases in antimicrobial
susceptibility occurred among PRSP in all geographical
regions (Additional file 2: Table S2), most notably in
North America where reductions were noted for
amoxicillin-clavulanate (p < 0.0001; 61.2% in 2004 and
35.2% in 2012), ceftriaxone (p < 0.0001; 89.1% in 2004 and
44.2% in 2009 [77.3% in 2012]), minocycline (p < 0.0001;
Table 5 Antimicrobial activity of antimicrobial agents against Streptococcus spp. collected globally between 2004 - 2013
MIC90 (mg/L) MIC range (mg/L) % susceptible % resistant
Streptococcus agalactiae (n = 12,819)
AMC 0.12 ≤0.03 – ≥ 16 - -
AMP 0.12 ≤0.06 – 0.25 100 -
CRO 0.12 ≤0.03 – 0.5 100 -
IPM (n = 2,511) 0.25 ≤0.12 – 8 - -
LVX 1 ≤0.06 – ≥ 64 98.6 1.1
LIN 1 ≤0.5 – 2 100 -
MEM (n = 10,308) ≤0.12 ≤0.12 – 1 99.9 -
MIN ≥16 ≤0.25 – ≥ 16 20.6 70.6
PEN 0.12 ≤0.06 – 0.12 100 -
TZP 0.5 ≤0.25 – ≥ 32 - -
TGC 0.12 ≤0.008 – 2 99.9 -
VAN 0.5 ≤0.12 – 1 100 -
Streptococcus pneumoniae (n = 14,562)
AMC 2 ≤0.03 – ≥ 16 92.8 3.5
AMP 4 ≤0.06 – ≥ 32 - -
AZM (n = 12,973) 64 ≤0.03 – ≥ 128 67.2 32.4
CRO 1 ≤0.03 – ≥ 128 95.0 1.2
CLR (n = 12,973) 64 ≤0.015 –≥ 128 67.5 32.0
CLI (n = 12,973) ≥128 ≤0.015 –≥ 128 80.8 18.9
ERY (n = 12,973) 64 ≤0.015 –≥ 128 66.8 32.7
IPM (n = 3,154) 0.5 ≤0.12 – ≥ 32 74.2 4.1
LVX 1 ≤0.06 – ≥ 64 98.9 0.7
LIN 1 ≤0.5 – 4 99.9 -
MEM (n = 11,408) 0.5 ≤0.12 – ≥ 32 81.4 10.0
MIN 8 ≤0.25 – ≥ 16 64.4 26.9
PEN 2 ≤0.06 – ≥ 16 61.9 14.8
TZP 2 ≤0.25 – ≥ 32 - -
TGC 0.06 ≤0.008 – 0.25 99.9 -
VAN 0.5 ≤0.12 – 1 100 -
Streptococcus pneumoniae, PRSP (n = 2,152)
AMC 8 ≤0.03 – ≥ 16 53.2 22.7
AZM (n = 1,971) ≥128 ≤0.03 – ≥ 128 21.5 78.0
CRO 2 0.06 –≥ 128 69.9 7.2
CLR (n = 1,971) ≥128 ≤0.015 –≥ 128 21.8 77.8
CLI (n = 1,971) ≥128 ≤0.015 –≥ 128 43.2 56.1
ERY (n = 1,971) ≥128 ≤0.015 –≥ 128 20.9 78.7
IPM (n = 357) 1 ≤0.12–≥ 32 1.4 29.7
LVX 1 ≤0.06 – ≥ 64 97.5 1.9
LIN 1 ≤0.5 – 2 100 -
MEM (n = 1,795) 1 ≤0.12 – ≥ 32 6.1 58.4
MIN ≥16 ≤0.25 – ≥ 16 27.6 60.3
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Table 5 Antimicrobial activity of antimicrobial agents against Streptococcus spp. collected globally between 2004 - 2013
(Continued)
TZP 8 ≤0.25 – ≥ 32 - -
TGC 0.03 ≤0.008 – 0.12 99.8 -
VAN 0.5 ≤0.12 – 1 100 -
AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; AZM, azithromycin; FEP, cefepime; CAZ, ceftazidime; CLR, clarithromycin; CLI, clindamycin; CRO,
ceftriaxone; ERY, erythromycin; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MIN, minocycline; PEN, penicillin; PRSP, penicillin-resistant S.
pneumoniae; TZP, piperacillin-tazobactam; TGC, tigecycline; VAN, vancomycin; VR, vancomycin-resistant.
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mycin (p < 0.001; 55.6% in 2004 and 32.1% in 2012), azi-
thromycin (p < 0.01; 18.3% in 2004 and 7.7% in 2012),
clarithromycin (p < 0.01; 19.0% in 2004 and 7.7% in 2012),
and erythromycin (p < 0.01; 17.5% in 2004 and 7.7% in
2012). (Additional file 2: Table S2).
Discussion
Statistically significant changes in antimicrobial susceptibil-
ity have been reported among all organisms monitored in
this study, with 410 such changes observed here; of these,
331 (81%) represented decreases in susceptibility. Globally,
significant changes were observed in 106 cases, 85 of which
(80%) denoted decreased susceptibility. Regionally, signifi-
cant susceptibility changes were most common in Europe
(71), Asia/Pacific Rim (67) and North America (68);
decreases in susceptibility were reported in 54 (76%), 65
(97%), and 53 (78%) of cases, respectively. Widespread
regional declines in antimicrobial susceptibility (or in-
creases in resistance) have previously been shown, in-
cluding Europe [11], Asia [12], and North America [13].
Statistically significant changes in susceptibility were
observed most often among A. baumannii (32), E. coli
(34), K. pneumoniae (30), and S. pneumoniae (31); among
these, significant decreases in susceptibility were observed
in 30 (94%), 33 (97%), 29 (97%) and 29 (94%) cases, re-
spectively. These changes reflect other recent reports of
declining susceptibility among important pathogens, in-
cluding P. aeruginosa [13], E. coli [14], K. pneumoniae
[15,16], and S. pneumoniae [17].
A. baumannii susceptibility decreased in this report,
both globally and regionally, to most antimicrobials;
47.1% of A. baumannii isolates from Asia/Pacific Rim
were MDR. Molton et al. [12] reported similar results,
with 55% of A. baumannii isolates from Singapore being
MDR. A. baumannii are adept at acquiring resistance
mechanisms and in expanding their global distribution
[18]; for example, meropenem susceptibility among A.
baumannii from a tertiary care teaching hospital in
Mexico decreased from 91.7% in 1999 to 11.8% in 2011
while imipenem susceptibility decreased from 88.2% to
13.9% [19]. These examples highlight the importance
of monitoring highly resistant pathogens such as A.
baumannii, which have the potential to become pan-
resistant [12].The activity of tigecycline against resistant clinical
bacteria collected globally in 2011 was described by
Sader et al. [20] as a part of the SENTRY Antimicrobial
Surveillance Program. Tigecycline susceptibility levels of
100% were reported among MRSA, 99.9% among ESBL-
positive E. coli, 99.5% among vancomycin-resistant
Enterococcus spp., 99.4% among PRSP, and 97.7% among
ESBL-positive Klebsiella spp.; also, a tigecycline MIC90
of 2 mg/L was reported by Sader et al. [20] for Acineto-
bacter. In a separate study, Sader et al. [21] reported
good tigecycline activity against clinical isolates collected
in the USA between 2006 and 2012, including MDR
phenotypes, with no upwards trends in tigecycline re-
sistance reported. These results accentuate the good
in vitro activity of tigecycline against resistance pheno-
types in the current study, including ESBL-positive and
carbapenem-resistant E. coli, vancomycin-resistant en-
terococci, MRSA, and PRSP. Tigecycline was also active
against carbapenem-resistant Enterobacter spp., with
95.4% of all isolates and 83.0% of carbapenem-resistant
isolates susceptible to tigecycline; the next most active
antimicrobial against carbapenem-resistant isolates was
amikacin, with 68.3% of isolates susceptible. The good
in vitro activity of tigecycline against resistant patho-
gens suggests it may have an important role in the treat-
ment of infections caused by these difficult-to-treat
pathogens.
Global susceptibility of Enterobacter spp., K. pneu-
moniae, S. marcescens, and S. pneumoniae to minocy-
cline increased in this study by ≥20% between 2011
and 2012; this increase has not been reported in previ-
ously published studies. The numbers of centres par-
ticipating in the TEST study increased globally from
197 in 2011 to 398 in 2012; this large influx of isolates
from new centres in 2012 may be responsible for the
observed susceptibility changes that year. This high-
lights one of the limitations of longitudinal surveil-
lance studies: inconsistent centre involvement over
time, with some centres contributing isolates in several
years but others in only a single year. Another bias in
TEST is the regional distribution of centres: Europe
and the US account for more than two thirds of the
centres participating in this study (72.9%, 443/608),
thus global results reported are heavily influenced by
trends in these regions.
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and changes in antimicrobial resistance as well as helping
to reduce the spread of resistant organisms. Longitudinal
surveillance studies such as the Study for Monitoring Anti-
microbial Resistance Trends (SMART), SENTRY, and
TEST are thus important tools in the development of
guidelines for rational empiric antimicrobial therapy
and, more immediately, directing local empiric therapy
[5,20,22,23]. The development and rapid distribution of
carbapenemases such as New Delhi metallo-β-lactamase
in recent years highlights the importance of multi-
national and global antimicrobial surveillance [24,25].
Conclusions
Antimicrobial susceptibility decreased both globally
and regionally between 2004 and 2013 in TEST among
clinically important pathogens such as A. baumannii
and E. coli. These results mirror decreases in anti-
microbial susceptibility shown in other surveillance
studies, such as SENTRY [20] and EARS-Net [11]. The
sustained high levels of susceptibility to tigecycline
among most of the pathogens examined in this study,
including multidrug-resistant pathogens such as ESBL-
positive E. coli and penicillin-resistant S. pneumoniae,
suggest that tigecycline may continue to be useful in
the treatment of infectious diseases in coming years.
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